PDL BioPharma, Inc.
PDL BIOPHARMA, INC. (Form: 8-K, Received: 06/07/2017 06:02:33)


 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 7, 2017

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)


Delaware
 
94-3023969
(State or Other Jurisdiction of Incorporation)
 
(I.R.S. Employer Identification No.)


932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
 






Item 7.01 Regulation FD Disclosure.
 
Beginning on June 7, 2017, PDL BioPharma, Inc. (the Company) will make presentations and participate in 
conferences with investors and analysts during the Jefferies 2017 Global Healthcare Conference in New York City, New York. A copy of the Company's presentation materials has been posted to the Company's website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This filing and the presentation include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s royalty assets or business are disclosed in the “Risk Factors” contained in the Company’s 2016 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2017, and updated in subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
 
Description
 
 
 
99.1
 
Presentation






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)
 
 
 
By:
 
/s/ Peter S. Garcia
 
 
Peter S. Garcia
 
 
Vice President and Chief Financial Officer




Dated: June 7, 2017






Exhibit Index


Exhibit No.
 
Description
99.1
 
Presentation







Exhibit 99.1

SLIDE1A44.JPG





SLIDE2A44.JPG





SLIDE3A44.JPG





SLIDE4A44.JPG





SLIDE5A44.JPG





SLIDE6A44.JPG





SLIDE7A44.JPG





SLIDE8A42.JPG





SLIDE9A41.JPG





SLIDK99.JPG





SLIDL01.JPG





SLIDL02.JPG





SLIDL03.JPG





SLIDL04.JPG





SLIDL05.JPG





SLIDL06.JPG





SLIDL07.JPG





SLIDL08.JPG





SLIDL09.JPG





SLIDL10.JPG





SLIDL11.JPG





SLIDL12.JPG





SLIDL13.JPG





SLIDL14.JPG





SLIDL15.JPG





SLIDL16.JPG





SLIDL17.JPG





SLIDL18.JPG





SLIDL19.JPG





SLIDL20.JPG





SLIDL21.JPG





SLIDL22.JPG





SLIDL23.JPG





SLIDL24.JPG





SLIDL25.JPG





SLIDL26.JPG





SLIDL27.JPG





SLIDL28.JPG





SLIDL29.JPG





SLIDL30.JPG





SLIDL31.JPG





SLIDL32.JPG





SLIDL33.JPG





SLIDL34.JPG





SLIDL35.JPG





SLIDL36.JPG





SLIDL37.JPG





SLIDL38.JPG





SLIDL39.JPG





SLIDL40.JPG





SLIDL41.JPG





SLIDL42.JPG





SLIDL43.JPG